Yoon J-H, Min KI, Kwag D, Min G-J, Park S-S, Park S, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Kim H-J, Min C-K, Cho S-G, Lee S. Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction. Haematologica; https://doi.org/10.3324/haematol.2025.300099 [Early view].